Analysis of commercially available snake antivenoms reveals high contents of endotoxins in some products
Analysis of commercially available snake antivenoms reveals high contents of endotoxins in some products
复制标题
DOI：
10.1016/j.toxcx.2024.100187
复制
发表时间：
2024-02-19
期刊：
影响因子：
--
通讯作者：
Leon，Guillermo
中科院分区：
文献类型：
--
作者：
Solano，Gabriela;Ainsworth，Stuart;Leon，Guillermo
作为注射治疗剂，抗蛇毒血清必须符合内毒素含量的规格。鲎试剂（LAL）试验用于评价几种市售抗蛇毒血清的内毒素含量。发现某些产品的内毒素浓度高于这些污染物的可接受限度。这些结果强调，需要包括内毒素测定的一部分，由制造商和管理机构的抗蛇毒血清的常规评价。
As injectable therapeutics, snake antivenoms must meet specifications for endotoxin content. TheLimulusamebocyte lysate (LAL) test was used to evaluate the endotoxin content in several commercially available antivenoms released for clinical use. It was found that some products have endotoxin concentrations higher than the accepted limit for these contaminants. These results emphasize the need to include endotoxin determination as part of the routine evaluation of antivenoms by manufacturers and regulatory agencies.